-

Catalent, Inc. to Present at the 9th Annual SVB Leerink Global Healthcare Conference

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE:CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today announced that Wetteny Joseph, Senior Vice President & Chief Financial Officer, will present at the 9th Annual SVB Leerink Global Healthcare Conference at 10:00 a.m. ET on Tuesday, February 25, 2020 in New York City.

A live webcast of the presentation will be accessible through the Company’s website at http://investor.catalent.com and will be available for replay following the event.

About Catalent, Inc.

Catalent, Inc. (NYSE:CTLT) is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs more than 13,000 people, including approximately 2,400 scientists, at more than 35 facilities across four continents and in fiscal 2019 generated over $2.5 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, please visit www.catalent.com.

More products. Better treatments. Reliably supplied.™

Contacts

Investors:
Paul Surdez, Catalent, Inc.
(732) 537-6325
investors@catalent.com

Catalent, Inc.

NYSE:CTLT

Release Versions

Contacts

Investors:
Paul Surdez, Catalent, Inc.
(732) 537-6325
investors@catalent.com

More News From Catalent, Inc.

Catalent and S.Biomedics Announce Partnership to Develop and Manufacture TED‑A9

TAMPA, Fla. & SEOUL, South Korea--(BUSINESS WIRE)--Catalent and S.Biomedics today announced a strategic partnership to support the development and manufacturing of TED‑A9, S.Biomedics’ allogeneic pluripotent stem-cell-derived ventral midbrain–specific dopaminergic precursor cell therapy being developed for the treatment of Parkinson’s disease. TED‑A9 represents S.Biomedics’ ambition to deliver a new class of regenerative medicine for patients with Parkinson’s disease. The program reflects years...

SmartCella and Catalent Sign Nonexclusive License Agreement for GMP iPSCs

TULLINGE, Sweden & TAMPA, Fla.--(BUSINESS WIRE)--SmartCella and Catalent have entered a nonexclusive license agreement for induced pluripotent stem cells (iPSCs) for developing regenerative therapies...

Catalent’s SMARTag® ADC Pipeline and New Enhanced Conjugates Offering Featured at 16th World ADC San Diego

TAMPA, Fla.--(BUSINESS WIRE)--Catalent, Inc. presented new advancements in its SMARTag® antibody-drug conjugate (ADC) technology at the 16th World ADC San Diego conference....
Back to Newsroom